| Patricia Eileen Cain, DPM | |
|
1510 Division St, Suite 80, Oregon City, OR 97045-1581 | |
| (503) 655-0775 | |
| (503) 655-0751 |
| Full Name | Patricia Eileen Cain |
|---|---|
| Gender | Female |
| Speciality | Podiatrist - Foot Surgery |
| Location | 1510 Division St, Oregon City, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518146984 | NPI | - | NPPES |
| 158763 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0131X | Podiatrist - Foot Surgery | DP00269 (Oregon) | Primary |
| Provider Name | Northwest Extremity Specialists Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1295126241 PECOS PAC ID: 3577881747 Enrollment ID: O20150420000860 |
News Archive
University of Connecticut Health Center scientist, Robert Reenan, has uncovered new rules of RNA recoding - a genetic editing method cells use to expand the number of proteins assembled from a single DNA code.
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.
Two studies in the April 21, 2006 Cell report new details of the "genetic program" that affords embryonic stem cells the flexibility to give rise to any cell type in the body. Both groups identified mechanisms by which the embryonic stem cells of mice or humans keep from going down any one particular developmental path-that of muscle or nervous tissue, for example-while remaining "poised for activation."
India has become the "premier drug provider for the developing world" by producing generic versions of some of the world's most effective medicines, including antiretroviral drugs, but the country's decision to adhere to international patent regulations could limit access to generic drugs in the developing world, the Christian Science Monitor reports.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patricia Eileen Cain, DPM 1510 Division St, Suite 80, Oregon City, OR 97045-1581 Ph: (503) 655-0775 | Patricia Eileen Cain, DPM 1510 Division St, Suite 80, Oregon City, OR 97045-1581 Ph: (503) 655-0775 |
News Archive
University of Connecticut Health Center scientist, Robert Reenan, has uncovered new rules of RNA recoding - a genetic editing method cells use to expand the number of proteins assembled from a single DNA code.
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.
Two studies in the April 21, 2006 Cell report new details of the "genetic program" that affords embryonic stem cells the flexibility to give rise to any cell type in the body. Both groups identified mechanisms by which the embryonic stem cells of mice or humans keep from going down any one particular developmental path-that of muscle or nervous tissue, for example-while remaining "poised for activation."
India has become the "premier drug provider for the developing world" by producing generic versions of some of the world's most effective medicines, including antiretroviral drugs, but the country's decision to adhere to international patent regulations could limit access to generic drugs in the developing world, the Christian Science Monitor reports.
› Verified 9 days ago